Press Releases SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
41.44 ^USD	+0.19%		+12.70%	+13.53%

Jul. 01	Sector Update: Health Care Stocks Mixed Premarket Monday	MT
Jul. 01	Sector Update: Health Care	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm	Jul. 02	PR
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Jul. 01	GL
SpringWorks Therapeutics : Termination of Material Agreement Form 8 K	Jun. 07	PU
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	Jun. 05	GL
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	May. 23	GL
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference	May. 08	GL
SpringWorks Therapeutics: Q1 Earnings Snapshot	May. 02	AQ
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates	May. 02	GL
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	Apr. 18	GL
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	Feb. 29	GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	Feb. 29	AQ
SpringWorks Therapeutics: Q4 Earnings Snapshot	Feb. 27	AQ
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	Feb. 27	GL
SpringWorks Therapeutics to Present at Upcoming Investor Conferences	Feb. 22	GL
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	AQ
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	GL
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Press Releases

Filters